Boston Life Sciences, Inc. to Present at Investor Luncheon in New York

    Business Editors/Biotech Writers

    BOSTON--(BUSINESS WIRE)--Feb. 7, 2005--Boston Life Sciences, Inc. (NASDAQ: BLSI), a biotechnology company focused in the diagnosis and treatment of central nervous system diseases, has announced that Peter Savas, the Company's Chairman and Chief Executive Officer, and Mark Pykett, President and Chief Operating Officer, will give an investor presentation and an overview of the Company at a luncheon in New York City on Tuesday, February 8, 2005, at 12:00PM EST.
    The luncheon will be hosted by Alexandros Partners LLC.
    Due to limited room capacity, please call Anthony Loumidis of Alexandros Partners as soon as possible at (781) 622-1117 to confirm availability and location.

    Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of novel diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE (R), the Company's lead program, is in PHASE III for the diagnosis of Parkinson's disease and Phase II for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include O-1369 for the treatment of Parkinson's disease and Inosine for the treatment of stroke. BLSI's current research collaborations include Harvard Medical School, Children's Hospital of Boston and the University of Massachusetts-Worcester.

    Statements made in this press release, other than statements of historical fact, represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, achievements and milestones, schedules of IND, NDA and all other regulatory submissions and the possible approval of products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, delays in the regulatory or development processes, results from clinical and pre-clinical trials, regulatory decisions, market acceptance of the Company's products, the ability to obtain intellectual property protection, the outcome of discussions with potential partners and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report or Form 10-K.

--30--AS/bo*

CONTACT: Joseph Hernon Chief Financial Officer Boston Life Sciences, Inc. (617) 425-0200 jhernon@bostonlifesciences.com

KEYWORD: MASSACHUSETTS NEW YORK INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY PRODUCT ADVISORY SOURCE: Boston Life Sciences, Inc.

Copyright Business Wire 2005